Vinblastinesulphate is a white or light yellow amorphous power, which is easily soluble in water. Vinblastine belongs to the group of cancer-fighting medications known as antineoplastics. Vinblastine is used alone or in combination with other antineoplastic medications to treat many different types of cancer including Hodgkin's disease, non-Hodgkin's lymphoma (cancer of the lymph cells), Kaposi's sarcoma, breast cancer, and testicular cancer. It kills cancer cells by interfering with the genetic material DNA, which is necessary for their growth and reproduction.
Periwinkle Plantation is mainly concentrated in China. The production volume was high during 2000s, with a kilo of Vinca alkaloids can be sold at 10 USD/gram. Now as the less plantation in Hainan Province, the cost of Periwinkle and Vinca alkaloids has hiked at 20 USD/ gram. Currenly there are less companies produce Vinca alkaloids, since many companies couldn’t survive after capital chain breaks. Globally, leading suppliers are Guangzhou Hanfang Pharmaceutical, Hainan Vinca Biological Medicine Technology and Guangzhou Person Pharmaceutical which are located in China. The three companies produced nealy 60% of global Vinblastinesulphate Vinkem from India also produce Vinblastinesulphate API for cancer treatment drugs.
Global Vinblastinesulphate (CAS 143-67-9) market size will increase to 21 Million US$ by 2025, from 19 Million US$ in 2018, at a CAGR of 1.1% during the forecast period. In this study, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Vinblastinesulphate (CAS 143-67-9).
This report researches the worldwide Vinblastinesulphate (CAS 143-67-9) market size (value, capacity, production and consumption) in key regions like United States, Europe, Asia Pacific (China, Japan) and other regions.
This study categorizes the global Vinblastinesulphate (CAS 143-67-9) breakdown data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
The following manufacturers are covered in this report:
Guangzhou Hanfang Pharmaceutical
Hainan Vinca Biological Medicine Technology
Guangzhou Person Pharmaceutical
Hainan Yueyang Biotechnology
Hubei Honch Pharmaceutical
Fine Chemicals Corporation
Hengtengfu Biological Products
Vinblastinesulphate (CAS 143-67-9) Breakdown Data by Type
Vinblastinesulphate (CAS 143-67-9) Breakdown Data by Application
Breast & Ovarian Cancer
Vinblastinesulphate (CAS 143-67-9) Production Breakdown Data by Region
Vinblastinesulphate (CAS 143-67-9) Consumption Breakdown Data by Region
Rest of Europe
Central & South America
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
The study objectives are:
To analyze and research the global Vinblastinesulphate (CAS 143-67-9) capacity, production, value, consumption, status and forecast;
To focus on the key Vinblastinesulphate (CAS 143-67-9) manufacturers and study the capacity, production, value, market share and development plans in next few years.
To focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.
To define, describe and forecast the market by type, application and region.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends and factors driving or inhibiting the market growth.
To analyze the opportunities in the market for stakeholders by identifying the high growth segments.
To strategically analyze each submarket with respect to individual growth trend and their contribution to the market.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of Vinblastinesulphate (CAS 143-67-9) :
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.